Home Cart Sign in  
Chemical Structure| 1608125-21-8 Chemical Structure| 1608125-21-8

Structure of AMG319
CAS No.: 1608125-21-8

Chemical Structure| 1608125-21-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AMG319 is an effective selective PI3Kδ inhibitor with an IC50 of 18 nM.

Synonyms: AMG319

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AMG319

CAS No. :1608125-21-8
Formula : C21H16FN7
M.W : 385.40
SMILES Code : C[C@H](NC1=C2N=CNC2=NC=N1)C3=CC4=CC=C(F)C=C4N=C3C5=NC=CC=C5
Synonyms :
AMG319
MDL No. :MFCD28902228
InChI Key :KWRYMZHCQIOOEB-LBPRGKRZSA-N
Pubchem ID :68947304

Safety of AMG319

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AMG319

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, IC50:850 nM

  • p110δ

    PI3Kδ, IC50:18 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human PMNs 1,000, 100, 10, 1, 0.1 nM 2 hours To evaluate the impact of AMG319 on immune complex-induced ROS release from PMNs. Results showed that AMG319 inhibited ROS release at doses close to the reported IC50. PMC8452940
Human PMNs 1,000, 100, 10, 1, 0.1 nM 2 hours To evaluate the impact of AMG319 on immune complex-induced ROS release from PMNs. Results showed that AMG319 inhibited ROS release at doses close to the reported IC50. PMC8452940
Human PMNs 1,000, 100, 10, 1, 0.1 nM 60 minutes To evaluate the impact of AMG319 on immune complex-induced ROS release from PMNs. Results showed that AMG319 inhibited ROS release at doses close to the reported IC50. PMC8452940
Neutrophils 1,000, 100, 10, 1, 0.1 nM 2 hours Evaluate the assembly of 5-LO/FLAP complex and its role in LT biosynthesis PMC8452940
Neutrophils 10 µM 2 hours Evaluate the assembly of 5-LO/FLAP complex and its role in LT biosynthesis PMC8452940
Neutrophils 1,000, 100, 10, 1, 0.1 nM 60 minutes Evaluate the assembly of 5-LO/FLAP complex and its role in LT biosynthesis PMC8452940
BmE cells 10 µM 72 hours To evaluate the inhibitory effect of AMG319 on BmNPV, qPCR results showed that the accumulated virus DNA was 60%, significantly inhibiting viral proliferation. PMC6480691
BmE cells 10 µM 72 hours To evaluate the inhibitory effect of AMG319 on BmNPV, qPCR results showed that the accumulated virus DNA was 60%, significantly inhibiting viral proliferation. PMC6480691

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice B16F10-OVA melanoma model Oral 75 mg/kg Daily administration until the end of the experiment To evaluate the effect of PI3Kδ inhibitor on the tumor microenvironment, results showed significant reduction in tumor volume, increased number of tumor-infiltrating CD8+ T cells, and enhanced cytotoxicity. PMC9132770
NOD-SCID mice TCL1-192 cell transplant model Drinking water administration 25 mg/kg Daily administration until death or reaching predetermined endpoints To evaluate the efficacy of AMG319 in combination with acalabrutinib in an aggressive CLL mouse model. Results showed that the combination significantly reduced tumor burden and extended survival. PMC5626587
Silkworm Silkworm larvae Oral 15 µg/g Only once To evaluate the inhibitory effect of AMG319 on BmNPV in silkworms, qPCR results showed that the viral DNA content was 57%, significantly inhibiting viral proliferation. PMC6480691

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.97mL

2.59mL

1.30mL

25.95mL

5.19mL

2.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories